Isamu Okamoto

32.9k citations

383 papers · 13.9k indexed · 8 hit papers · h-index 61

Oncology top 0.1%
- Lung Cancer Research Studies 128
- Colorectal Cancer Treatments and Studies 89
- Cancer Immunotherapy and Biomarkers 49
Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations 275
- Lung Cancer Diagnosis and Treatment 64
- Gastric Cancer Management and Outcomes 34
Cancer Research top 0.5%
- Cancer Genomics and Diagnostics 37
Hepatology top 2%
Molecular Biology top 1%
- Cancer therapeutics and mechanisms 34

Co-authors: Kazuhiko Nakagawa Masahiro Fukuoka Kazuto Nishio Nobuyuki Yamamoto Masayuki Takeda Yoichi Nakanishi Takashi Seto Kazuko Sakai
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: Journal of Clinical Oncology (49 papers)Annals of Oncology (46 papers)Journal of Thoracic Oncology (35 papers)
Partner nations: Japan United States South Korea

In The Last Decade

Isamu Okamoto

373 papers receiving 13.7k citations

Hit Papers

8 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2023 Nature Communications
2020 Journal of Thoracic Oncology
2018 Journal of Clinical Oncology
2015 Clinical Cancer Research
2014 Annals of Oncology
2014 The Lancet Oncology
2013 Journal of Clinical Oncology
2012 Journal of Clinical Oncology

Peers

Countries citing papers authored by Isamu Okamoto

Since Specialization

Citations

This map shows the geographic impact of Isamu Okamoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isamu Okamoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isamu Okamoto more than expected).

Fields of papers citing papers by Isamu Okamoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isamu Okamoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isamu Okamoto. The network helps show where Isamu Okamoto may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Isamu Okamoto, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Isamu Okamoto Line = papers co-authored together Isamu Okamoto links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy Cancer Research ·John Bracken,Hyun-Suk Jin,Doh-Yoon Kim,Masaki Magari,今忠正,Youki Ueda,Takamasa Ishino,Joji Nagasaki,Tomohiro Fujiwara,Hidetaka Yamamoto,Hidetoshi Hayashi,Kota Tachibana,Joji Ishida,Yoshihiro Otani,K. Söllner,Shinichi Toyooka,Isamu Okamoto,Yosuke Togashi	2025	2
2	Association Between Single Nucleotide Polymorphisms and Disease Susceptibility, Survival, and Acute Exacerbation in Idiopathic Pulmonary Fibrosis Respirology ·Kazuya Tsubouchi,Toyoshi Yanagihara,Fumiaki Kiyomi,Yuzo Yamamoto,You-Ren Ding,S. Zhihui,Solony Afra Pires Levy,Shohei Takata,Hiroshi Ishii,Yasuhiko Kitasato,Masaki Okamoto,Satoru Kawakami,Kazuhiro Yatera,映虎杨,Masaki Fujita,Kelly A. Benner,Chikako Kiyohara,Jens Auken,Isamu Okamoto	2025	0
3	AXL‐Mediated Drug Resistance in ALK‐Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts Cancer Science ·A. B. Adler,Bruna Landeiro Tavares,Yosuke Seto,Ken Uchibori,Makoto Nishio,Isamu Okamoto,Ryohei Katayama	2025	1
4	MA17.04 Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following cCRT in Limited-Stage SCLC: ADRIATIC Journal of Thoracic Oncology ·Rama Tri Budi Ardianto,Ying Cheng,David R. Spigel,Jian Fang,Yuanbin Chen,Yoshitaka Zenke,Ki Hyeong Lee,Alejandro Navarro,Garima Tomar,Deisy Yolima Lopez Grijalba,Isamu Okamoto,Mustafa Özgüroğlu,Linay Yuderkys,E. V. Oleynikova,Sayed M.S. Hashemi,Robert Turner,Helen Mann,Timothy K. Wolff,Haiyi Jiang,Suresh Senan	2024	1
5	Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. Journal of Clinical Oncology ·James Chih‐Hsin Yang,R蒘 SALVARREDI,Jong Seok Lee,Yun Fan,Filippo de Marinis,Isamu Okamoto,Takako Inoue,Ahmed Nedjari,Zhang Li,Cheng‐Ta Yang,Emmanuel de la Mora Jimenez,Jianying Zhou,M. Pérol,Ki Hyeong Lee,David Vicente,Eiki Ichihara,Gregory J. Riely,Yiwen Luo,Niyati Bhagwati,Shun Lü	2023	50
6	Mass cytometry identifies characteristic immune cell subsets in bronchoalveolar lavage fluid from interstitial lung diseases Frontiers in Immunology ·박솔,Toyoshi Yanagihara,Soriano Panchana Diana María,Tuychiyeva Nodira Saitov Sirojiddin,Kunihiro Suzuki,Kazuya Tsubouchi,Daisuke Eto,Hiroyuki Ando,Jean-Pierre Mazimann,Satoshi Ikegame,Yoshihiro Baba,Yoshinori Fukui,Isamu Okamoto	2023	24
7	MicroRNA‐326 negatively regulates CD155 expression in lung adenocarcinoma Cancer Science ·Sevinç Hatipoğlu,Yasuto Yoneshima,Koji Okamura,Toyoshi Yanagihara,Mikiko Hashisako,Takeshi Iwasaki,Naoki Haratake,فتحي حسن بليلة آدم,Keiichi Ota,Eiji Iwama,Tomoyoshi Takenaka,Kentaro Tanaka,Tomoharu Yoshizumi,Yoshinao Oda,Isamu Okamoto	2023	4
8	Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors Lung Cancer ·Lingfeng Shi,Hiroyuki Inoue,Yoshimasa Shiraishi,Andrew Okhrimenko,Sevinç Hatipoğlu,Hiroyuki Ando,Jean Jacques Staub,Б.А. Леко,Hiroaki Ogata,Koji Okamura,Shinichi Kimura,Tomohiro Ogawa,Keiichi Ota,Yasuto Yoneshima,Kentaro Tanaka,Naoki Hamada,Isamu Okamoto,Eiji Iwama	2023	8
9	Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancerbreakdown → Clinical Cancer Research ·Keiichi Ota,Koichi Azuma,Akihiko Kawahara,Satoshi Hattori,Eiji Iwama,Junko Tanizaki,Taishi Harada,Koichiro Matsumoto,Koichi Takayama,Shinzo Takamori,Masayoshi Kage,Tomoaki Hoshino,Yoichi Nakanishi,Isamu Okamoto	2015	366
10	Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer Clinical Cancer Research ·Takeshi Yoshida,Guolin Zhang,Matthew A. Smith,Heba Koraitin,Yun Bai,Jiannong Li,Bin Fang,John M. Koomen,Bhupendra Rawal,Kate Fisher,Y. Ann Chen,Valentina Paterno,Lene Renate Dyhring Rossebø,Haruka Yamaguchi,Kiyoko Shibata,Takafumi Okabe,Isamu Okamoto,Kazuhiko Nakagawa,Eric B. Haura	2014	89
11	Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer Clinical Cancer Research ·Junko Tanizaki,Isamu Okamoto,Takafumi Okabe,Kazuko Sakai,Kaoru Tanaka,Hidetoshi Hayashi,Hiroyasu Kaneda,Ken Takezawa,Kiyoko Kuwata,Haruka Yamaguchi,Erina Hatashita,Kazuto Nishio,Kazuhiko Nakagawa	2012	126
12	Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification Molecular Cancer Therapeutics ·Wataru Okamoto,Isamu Okamoto,Tokuzo Arao,Kiyoko Kuwata,Erina Hatashita,Haruka Yamaguchi,Kazuko Sakai,Kazuyoshi Yanagihara,Kazuto Nishio,Kazuhiko Nakagawa	2012	73
13	Overcoming Erlotinib Resistance in EGFR Mutation–Positive Non–Small Cell Lung Cancer Cells by Targeting Survivin Molecular Cancer Therapeutics ·Kunio Okamoto,Isamu Okamoto,Erina Hatashita,Kiyoko Kuwata,Haruka Yamaguchi,Aya Kita,Kentaro Yamanaka,Mayumi Ono,Kazuhiko Nakagawa	2011	59
14	Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer Clinical Cancer Research ·Ken Takezawa,Isamu Okamoto,Kazuto Nishio,Pasi A. Jänne,Kazuhiko Nakagawa	2011	115
15	Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors Molecular Cancer Therapeutics ·Isamu Okamoto,Hiroyasu Kaneda,Taroh Satoh,Wataru Okamoto,Masaki Miyazaki,Ryotaro Morinaga,Shinya Ueda,Masaaki Terashima,Asuka Tsuya,Akiko Sarashina,Daniela Saes Sarotelli,Tokuzo Arao,Kazuto Nishio,R. Kaiser,Kazuhiko Nakagawa	2010	79
16	Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase–Targeted Agents in Non–Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor Molecular Cancer Therapeutics ·Ken Takezawa,Isamu Okamoto,Junko Tanizaki,Kiyoko Kuwata,Haruka Yamaguchi,Masahiro Fukuoka,Kazuto Nishio,Kazuhiko Nakagawa	2010	63
17	FOXQ1 Is Overexpressed in Colorectal Cancer and Enhances Tumorigenicity and Tumor Growth Cancer Research ·Hiroyasu Kaneda,Tokuzo Arao,Kaoru Tanaka,Daisuke Tamura,Keiichi Aomatsu,Kanae Kudo,Kazuko Sakai,Marco A. De Velasco,Kunio Matsumoto,Yoshihiko Fujita,Yasuhide Yamada,Junji Tsurutani,Isamu Okamoto,Kazuhiko Nakagawa,Kazuto Nishio	2010	157
18	Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition Molecular Cancer Therapeutics ·Wataru Okamoto,Isamu Okamoto,Takeshi Yoshida,Kunio Okamoto,Ken Takezawa,Erina Hatashita,Yuki Yamada,Kiyoko Kuwata,Tokuzo Arao,Kazuyoshi Yanagihara,Masahiro Fukuoka,Kazuto Nishio,Kazuhiko Nakagawa	2010	58
19	Role of Survivin in EGFR Inhibitor–Induced Apoptosis in Non–Small Cell Lung Cancers Positive for EGFR Mutations Cancer Research ·Kunio Okamoto,Isamu Okamoto,Wataru Okamoto,Kaoru Tanaka,Ken Takezawa,Kiyoko Kuwata,Haruka Yamaguchi,Kazuto Nishio,Kazuhiko Nakagawa	2010	75
20	Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells Clinical Cancer Research ·Tsutomu Iwasa,Isamu Okamoto,Minoru Suzuki,Erina Hatashita,Yuki Yamada,Masahiro Fukuoka,Koji Ono,Kazuhiko Nakagawa	2009	51

About Isamu Okamoto

Isamu Okamoto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 383 papers that have together received 13.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (275 papers), Lung Cancer Research Studies (128 papers), Colorectal Cancer Treatments and Studies (89 papers), Lung Cancer Diagnosis and Treatment (64 papers), Cancer Immunotherapy and Biomarkers (49 papers), Cancer Genomics and Diagnostics (37 papers), Gastric Cancer Management and Outcomes (34 papers) and Cancer therapeutics and mechanisms (34 papers). The work is most often cited by research in Oncology (9.5k citations), Pulmonary and Respiratory Medicine (9.4k citations) and Cancer Research (2.0k citations). Isamu Okamoto has collaborated with scholars based in Japan, United States and South Korea. Frequent co-authors include Kazuhiko Nakagawa, Masahiro Fukuoka, Kazuto Nishio, Nobuyuki Yamamoto, Masayuki Takeda, Yoichi Nakanishi, Takashi Seto, Kazuko Sakai, Eiji Iwama and Junko Tanizaki. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer and Cancer Science.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact